Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
688 participants
INTERVENTIONAL
2011-12-31
2013-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 3 Papulopustular Rosacea Study
NCT01493687
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
NCT01355471
Azelaic Acid on Demodex Counts in Rosacea
NCT03035955
Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea
NCT01555463
Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle
NCT02547441
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CD5024
CD5024 1% Cream
CD5024
CD5024 1% Cream, once daily
CD5024 Vehicle
CD5024 Vehicle Cream
Azelaic acid 15% Gel
Topical Gel applied twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CD5024
CD5024 1% Cream, once daily
Azelaic acid 15% Gel
Topical Gel applied twice daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The subject has at least 15 but not more than 70 inflammatory lesions (papules and pustules) on the face.
Exclusion Criteria
2. The subject has rosacea with more than two nodules on the face.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Galderma R&D
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Graeber, M.D.
Role: STUDY_DIRECTOR
Galderma R&D, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Total Skin and Beauty
Birmingham, Alabama, United States
Coastal Clinical Research, Inc.
Mobile, Alabama, United States
Burke Pharmaceutical Research
Hot Springs, Arkansas, United States
Dermatology Specialists, Inc
Oceanside, California, United States
Integrated Research Group, Inc
Riverside, California, United States
Therapeutics Clinical Research
San Diego, California, United States
University of California, San Francisco
San Francisco, California, United States
ATS Clinical Research
Santa Monica, California, United States
Redwood Dermatology Research
Santa Rosa, California, United States
FXM Research Corp Miami
Miami, Florida, United States
Leavitt Medical Associates of Florida dba Ameriderm Research
Ormond Beach, Florida, United States
Atlanta Dermatology, Vein & Research Center, LLC
Alpharetta, Georgia, United States
Emory University
Atlanta, Georgia, United States
Altman Dermatology Associates
Arlington Heights, Illinois, United States
Northwestern University
Chicago, Illinois, United States
Deaconess Clinic, Inc.
Evansville, Indiana, United States
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, United States
Dermatology Specialists Research
Louisville, Kentucky, United States
Northeast Dermatology Associates
Beverly, Massachusetts, United States
David Fivenson, MD, PLC
Ann Arbor, Michigan, United States
Hamzavi Dermatology
Fort Gratiot, Michigan, United States
Somerset Skin Centre
Troy, Michigan, United States
Dermatology Clinical Trials Unit
St Louis, Missouri, United States
Psoriasis Treatment Center of NJ
West Windsor, New Jersey, United States
Academic Dermatology Associates
Albuquerque, New Mexico, United States
DermResearch Center of New York, Inc
Stony Brook, New York, United States
High Point, North Carolina, United States
PMG Research of Raleigh, LLC
Raleigh, North Carolina, United States
Oregon Dermatology and Research Center
Portland, Oregon, United States
Dermatology and Skin Surgery Center
Exton, Pennsylvania, United States
Philadelphia Institute of Dermatology
Fort Washington, Pennsylvania, United States
Penn State Hershey Medical Center
Hershey, Pennsylvania, United States
Paddington Research
Philadelphia, Pennsylvania, United States
Yardley Dermatology Associates
Yardley, Pennsylvania, United States
The Skin Wellness Center
Knoxville, Tennessee, United States
Dermatology Reserach Associates
Nashville, Tennessee, United States
Arlington Research Center, Inc
Arlington, Texas, United States
Stephen Miller MD
San Antonio, Texas, United States
San Antonio, Texas, United States
Center for Clinical Studies
Webster, Texas, United States
Guildford Dermatology Specialists
Surrey, British Columbia, Canada
Ultranova Skincare
Barrie, Ontario, Canada
Dermatrials Research
Hamilton, Ontario, Canada
The Guenther Dermatology Research Center
London, Ontario, Canada
Lynderm Research Inc
Markham, Ontario, Canada
North Bay Dermatology Centre, Inc
North Bay, Ontario, Canada
The Centre for Dermatology & Cosmetic Surgery
Richmond Hill, Ontario, Canada
XLR8 Medical Research, Inc
Windsor, Ontario, Canada
International Dermatology Research, Inc
Montreal, Quebec, Canada
Centre de Recherche Dermatologique du Quebec Metropolitan
Québec, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RD.06.SPR.18171
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.